Skip to content
OpenCapital
Get started

Krystal Biotech, Inc. KRYS Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies

Merck & Co. logo
Merck & Co.MRK
——
Viatris logo
ViatrisVTRS
——

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
Enterprise value$9.77B+44.2%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0×0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Krystal Biotech, Inc. (KRYS) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $124.76 in Q1 2026.
How has Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price increased by 34.2% year-over-year, from $92.94 to $124.76.
What is the long-term trend for Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a 19.8% compound annual growth rate (CAGR), from $40.31 to $99.45.